Regencell Bioscience Holdings Limited

NasdaqCM:RGC Stock Report

Market Cap: US$67.3m

Regencell Bioscience Holdings Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Yat-Gai Au

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure11yrs
CEO ownership81.2%
Management average tenure3.2yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Regencell Bioscience Holdings' (NASDAQ:RGC) Cash Burn Situation

Nov 18
Here's Why We're Not Too Worried About Regencell Bioscience Holdings' (NASDAQ:RGC) Cash Burn Situation

Slow And Steady Wins The Race With Regencell Bioscience

Aug 16

CEO

Yat-Gai Au (51 yo)

11yrs

Tenure

Mr. Yat-Gai Au serves as the Chief Financial Officer of Armitage Technologies Holding Ltd. Mr. Au served as Compliance Officer and Executive Director of Armitage Technologies Holding Ltd. He joined Armitag...

Leadership Team

NamePositionTenureCompensationOwnership
Yat-Gai Au
Founderno datano data81.22%
$ 54.6m
Michelle Chan
Financial Controller & Principal Financial Officer3.2yrsno datano data
Wai Hong Chung
COO, Chief Strategy Officer & Director3.4yrsUS$245.64kno data
Antonia Assang
Senior Vice President of Project Managementno datano datano data
Yat-Pui Au
Chief Business Officer1.9yrsno datano data

3.2yrs

Average Tenure

50yo

Average Age

Experienced Management: RGC's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yat-Gai Au
Founder11yrsno data81.22%
$ 54.6m
Wai Hong Chung
COO, Chief Strategy Officer & Director1.1yrsUS$245.64kno data
Yee Wah Hui
Independent Director3.5yrsno datano data
Paul J. Niewiadomski
Independent Director3.5yrsno datano data
Wing-Yan Lo
Independent Director3.1yrsno datano data

3.5yrs

Average Tenure

52yo

Average Age

Experienced Board: RGC's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 05:09
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Regencell Bioscience Holdings Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution